How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-anti-diabetics-oad.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Oral Anti Diabetics (OAD) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Anti Diabetics (OAD) (Oral Anti Diabetics (OAD)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral Anti-Diabetic Agents (multiple classes). Area: Diabetes.

marketed Oral Anti-Diabetic Agents (multiple classes) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Oral Anti Diabetics (OAD) (Oral Anti Diabetics (OAD)) — Sanofi. Oral anti-diabetics are a class of medications that lower blood glucose through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral Anti Diabetics (OAD) TARGET	Oral Anti Diabetics (OAD)	Sanofi	marketed	Oral Anti-Diabetic Agents (multiple classes)
Oral anti-diabetic drugs	Oral anti-diabetic drugs	Sanofi	phase 3	Oral anti-diabetic agents (multiple classes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral Anti-Diabetic Agents (multiple classes) class)

Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral Anti Diabetics (OAD) — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-anti-diabetics-oad. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab